Want to see BLTE full AI Analyst Report?
BLTE Stock Chart & Stats
$156.69
$5.07(3.31%)
At close: 4:00 PM EDT
$156.69
$5.07(3.31%)
Day’s Range― - ―
52-Week Range$88.00 - $200.00
Previous Close$157.3
Volume136.54K
Average Volume (3M)174.16K
Market Cap
$6.22B
Enterprise Value$5.30B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Nov 17, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding40,272,144
10 Day Avg. Volume179,576
30 Day Avg. Volume174,155
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)6.96
Price to Sales (P/S)0.00
P/FCF Ratio-144.35
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-46.42
Forecast
1Y Price Target
$236.86Price Target Upside51.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressFDA acceptance and Priority Review establish a defined path toward a potential U.S. decision, reducing regulatory uncertainty over the next several months. The milestone also supports commercialization planning and could enable Belite to become an early entrant in Stargardt disease treatment.
Phase 3 Efficacy SignalThe Phase 3 QAF result supports tinlarebant’s proposed mechanism and suggests potential disease-modifying activity in Stargardt disease. If sustained through regulatory review and future development, this evidence could strengthen differentiation and support adoption in an area with limited treatment options.
Capital StrengthExtremely low leverage gives Belite substantial financial flexibility while it advances regulatory and commercialization activities. A large equity base relative to debt reduces balance-sheet pressure and allows more capital to remain focused on clinical development, launch preparation, and pipeline expansion.
Bears Say
Pre-Revenue ModelBelite has no established product revenue to offset development and commercial preparation costs, leaving its financial outlook dependent on regulatory approval and eventual market uptake. Until monetization begins, the company cannot rely on operating revenue to fund its business or validate commercial economics.
Widening LossesThe sharply widening loss profile shows that operating expenses are increasing faster than the company’s ability to generate income, which remains absent before approval. Continued losses could reduce financial flexibility over time and make successful execution of the lead program increasingly important.
Persistent Cash BurnSustained negative operating and free cash flow means Belite consumes cash as it funds clinical programs and prepares for commercialization. Even with substantial capital currently available, continued spending raises the long-term need for disciplined allocation and potentially additional financing before revenue materializes.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $88.00 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $6.22B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Aug 13, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.777 by $0.077.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.79.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 40,272,144 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.777. Following the earnings report the stock price went down -7.075%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$236.86 (51.16% Upside)
$236.86 (51.16% Upside)
Blogger Sentiment
Neutral
BLTE Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 285.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.90%
12-Months-Change
Fundamentals
Return on Equity
-15.65%
Trailing 12-Months
Asset Growth
406.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed substantial positive progress: NDA acceptance with priority review and a clear PDUFA date, supportive Phase 3 QAF data, strong cash balance ($780M), a pediatric program, and high patient compliance. Counterbalancing these positives are materially higher R&D and SG&A expenses, a widening net loss, a confidential one‑time royalty payment, limited disclosure on manufacturing inspection status, and a delayed GA interim readout. The positives (regulatory momentum, strong efficacy signal, and financial runway) outweigh the operational and expense-related concerns.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$236.86
▲(51.16% Upside)
Technical Analysis
PTC Therapeutics
―
Travere Therapeutics
―
Xenon
―
Rhythm Pharmaceuticals
―
Mirum Pharmaceuticals
―
Ownership Overview
0.30% Insiders
0.81% Mutual Funds
<0.01% Other Institutional Investors
98.78% Public Companies and
Individual Investors